Targeting JAK2/STAT3 for the treatment of cancer: A review on recent advancements in molecular development using structural analysis and SAR investigations
Related Experiment Video
Updated: Jul 5, 2025
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Rupali Kohal1, Priya Bisht1, Ghanshyam Das Gupta2
1Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga 142 001, (Punjab), India.
Abstract:
Cancer is indeed considered a hazardous and potentially life-threatening disorder. The JAK/STAT pathway is an important intracellular signaling cascade essential for many physiological functions, such as immune response, cell proliferation, and differentiation. Dysregulation of this pathway aids in the progression and development of cancer. The downstream JAK2/STAT3 signaling cascades are legitimate targets against which newer anticancer drugs can be developed to prevent and treat cancer. Understanding the mechanisms behind JAK2/STAT3 participation in cancer has paved the way for developing innovative targeted medicines with the potential to improve cancer treatment outcomes. This article provides information on the current scenario and recent advancements in the design and development of anticancer drugs targeting JAK2/STAT3, including structural analysis and SAR investigations of synthesized molecules. Numerous preclinical and clinical trials are ongoing on these inhibitors, which are highlighted to gain more insight into the broader development prospects of inhibitors of JAK2/STAT3.
Insights
Targeting the JAK2/STAT3 pathway offers a promising strategy for developing novel anticancer drugs. Research focuses on inhibitors to combat cancer progression and improve treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway is crucial for normal cellular functions.
- Aberrant JAK/STAT signaling, particularly JAK2/STAT3, is implicated in various cancers.
- Targeting this pathway presents a therapeutic opportunity for cancer treatment.
Purpose of the Study:
- To review recent advancements in the design and development of anticancer drugs targeting JAK2/STAT3.
- To explore structural analyses and structure-activity relationship (SAR) studies of synthesized JAK2/STAT3 inhibitors.
- To highlight ongoing preclinical and clinical trials for these inhibitors.
Main Methods:
- Review of current literature on JAK2/STAT3 inhibitors.
- Analysis of structural data and SAR of synthesized compounds.
- Summarization of preclinical and clinical trial data.
Main Results:
- Several novel anticancer agents targeting JAK2/STAT3 have been designed and synthesized.
- Structural and SAR studies provide insights into inhibitor efficacy and specificity.
- Ongoing trials demonstrate the potential of these inhibitors in cancer therapy.
Conclusions:
- Targeting the JAK2/STAT3 pathway is a viable strategy for novel cancer drug development.
- Continued research and clinical trials are essential to realize the full therapeutic potential of JAK2/STAT3 inhibitors.
- These targeted therapies hold promise for improving cancer treatment outcomes.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020